This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if a…

T-cell LymphomasNK-Cell LymphomasT-cell Prolymphocytic Leukemia+1 more

~Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05010005

Phase 2

A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractor…

Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more

~Estimated

~$10 – $7,500

Seda S. ToluNCT07283822